<DOC>
	<DOC>NCT00692952</DOC>
	<brief_summary>A multicentric clinical trial in three Chinese Maternal and Child Hospitals was conducted to evaluate the efficacy, safety and acceptability of newly-developed vaginal contraceptive gel, the optimized benzalkonium chloride (BZK) gel containing 18mg BZK, with comparison to a currently marketed (in China)contraceptive gel LELEMIÂ® containing 50mg Nonoxynol-9 (N-9).</brief_summary>
	<brief_title>Effectiveness of BenZalkonium Chloride Gel as Vaginal Contraceptive: a Multicentric Randomized Controlled Trial</brief_title>
	<detailed_description>A phase II, multicentric,randomized, controlled clinical trial.</detailed_description>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Nonoxynol</mesh_term>
	<mesh_term>Benzalkonium Compounds</mesh_term>
	<criteria>at risk for pregnancy and desiring contraception having regular menstrual cycle (2135 days) at low risk for HIV or other sexually transmitted infection sexually active use the test products as their primary method of contraception keep a diary of coital activity, product use, and adverse events diagnosis of any vaginal infection or any symptom of STDs at baseline known allergy or hypersensitivity to N9 or BZK menopause for more than one month breastfeeding vaginal bleeding with unknown reasons genitourinary system anomaly hysteroptosis II or severe cystocele moderate to severe erosion of cervix malignant reproductive system tumors</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>contraceptive efficacy</keyword>
</DOC>